Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA
Filippo Cademartiri/LinkedIn
Jan 27, 2026, 13:48

Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA

Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn:

”Three biomarkers are better than one: refining ASCVD risk in MESA

Traditional risk assessment often treats biomarkers in isolation.

This large analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) shows why that approach may miss the people at highest cardiovascular risk.

What was studied?
Researchers evaluated the individual and combined effects of:

Lipoprotein(a) [Lp(a)]
High-sensitivity CRP (hs-CRP)
Total homocysteine (tHcy)

on coronary heart disease (CHD) and stroke over ~16 years of follow-up in >6,600 asymptomatic adults.

Key findings

Alone, biomarkers showed modest or inconsistent associations.
Risk rose sharply only when biomarkers were elevated together.
Individuals with all three elevated had:

~2× higher risk of CHD
~3× higher risk of stroke

In contrast, having just one elevated marker often did not meaningfully increase risk after adjustment.

Why this matters
This study highlights a core limitation of single-marker thinking:

ASCVD risk is multidimensional
Inflammation, thrombosis, and atherogenesis interact
“Average” risk estimates can obscure high-risk biological phenotypes

Notably, homocysteine—not currently a guideline risk enhancer—emerged as a powerful amplifier of risk when combined with inflammation and Lp(a).

Important nuance
Adding these biomarkers only modestly improved population-level prediction metrics (C-statistics). But for individual risk stratification, the signal is clinically meaningful.

Take-home message
ASCVD risk is not additive—it’s synergistic.
Looking at biomarker combinations, rather than single values, may better identify who truly carries residual cardiovascular risk.

Precision prevention beats one-number medicine.”

Read the full article here.

Article: Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis

Authors: Sarah O. Nomura, Harpreet S. Bhatia, Parveen K. Garg, Amy B. Karger, Weihua Guan, Jing Cao, Michael D. Shapiro, Michael Y. Tsai

Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA

Stay updated on all scientific advances with Hemostasis Today.

ASCVD Atherosclerosis CRP Filippo Cademartiri Health Hematology Hemostasis Hemostasis News Hemostasis Today Homocysteine Lp(a) Medicine MESA thrombosis
NewsFeed